NCT07049133View on ClinicalTrials.gov

Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic Breast Cancer
Interventions
OTHER

T-DXd toxicity marker identification

to find potential predictive markers associated with T-DXd-related toxicities

Trial Locations (1)

20141

European Institute of Oncolgy, Milan

All Listed Sponsors
lead

European Institute of Oncology

OTHER